Gregory Michael Brown

Dr. Gregory Michael Brown

Collaborator Scientist, Centre for Addiction and Mental Health, University of Toronto Departmant of Psychiatry
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
LBLindsay M. Melhuish Beaupre
Lindsay M. Melhuish Beaupre
GBGregory Michael Brown
Gregory Michael Brown
VGVanessa F. Gonçalves
Vanessa F. Gonçalves
JKJames L. Kennedy
James L. Kennedy
Melatonin is an ancient molecule that is evident in high concentrations in various tissues throughout the body. It can be separated into two pools; one of which is synthesized by the pineal and can be found in blood, and the second by various tissues and is present in these tissues. Pineal melatonin levels display a circadian rhythm while tissue melatonin does not. For decades now, melatonin has been implicated in promoting and maintaining sleep. More recently, evidence indicates that it also plays an important role in neuroprotection. The beginning of our review will summarize this literature. As an amphiphilic, pleiotropic indoleamine, melatonin has both direct actions and receptor-mediated effects. For example, melatonin has established effects as an antioxidant and free radical scavenger both in vitro and in animal models. This is also evident in melatonin’s prominent role in mitochondria, which is reviewed in the next section. Melatonin is synthesized in, taken up by, and concentrated in mitochondria, the powerhouse of the cell. Mitochondria are also the major source of reactive oxygen species as a byproduct of mitochondrial oxidative metabolism. The final section of our review summarizes melatonin’s potential role in aging and psychiatric disorders. Pineal and tissue melatonin levels both decline with age. Pineal melatonin declines in individuals suffering from psychiatric disorders. Melatonin’s ability to act as a neuroprotectant opens new avenues of exploration for the molecule as it may be a potential treatment for cases with neurodegenerative disease.

26 November 2020 in Diseases
Verified
Journal Article
Open access
PDF file
DCDaniel Cardinali
Daniel Cardinali
GBGregory Michael Brown
Gregory Michael Brown
Seithikurippu R. Pandi-PerumalSeithikurippu R. Pandi-Perumal
Seithikurippu R. Pandi-Perumal
The therapeutic potential of melatonin as a chronobiotic cytoprotective agent to counteract the consequences of COVID-19 infections has been advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, and immunomodulatory compound, melatonin could be unique in impairing the consequences of SARS-CoV-2 infection. Moreover, indirect evidence points out to a possible antiviral action of melatonin by interfering with SARS-CoV-2/angiotensin-converting enzyme 2 association. Melatonin is also an effective chronobiotic agent to reverse the circadian disruption of social isolation and to control delirium in severely affected patients. As a cytoprotector, melatonin serves to combat several comorbidities such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases, which aggravate COVID-19 disease. In view of evidence on the occurrence of neurological sequels in COVID-19-infected patients, another putative application of melatonin emerges based on its neuroprotective properties. Since melatonin is an effective means to control cognitive decay in minimal cognitive impairment, its therapeutic significance for the neurological sequels of SARS-CoV-2 infection should be considered. Finally, yet importantly, exogenous melatonin can be an adjuvant capable of augmenting the efficacy of anti-SARS-CoV-2 vaccines. We discuss in this review the experimental evidence suggesting that melatonin is a potential “silver bullet” in the COVID 19 pandemic.


6 May 2021 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
LBLindsay M. Melhuish Beaupre
Lindsay M. Melhuish Beaupre
GBGregory Michael Brown
Gregory Michael Brown
NBNicole A. Braganza
Nicole A. Braganza
JKJames L. Kennedy
James L. Kennedy
VGVanessa F. Gonçalves
Vanessa F. Gonçalves
The biology underlying sleep is not yet fully elucidated, but it is known to be complex and largely influenced by circadian rhythms. Compelling evidence supports of a link among circadian rhythms, ...

1 January 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
GBGregory Michael Brown
Gregory Michael Brown
RMRoger McIntyre
Roger McIntyre
JRJoshua Rosenblat
Joshua Rosenblat
RHRuediger Hardeland
Ruediger Hardeland

26 September 2018 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
LBLindsay Melhuish Beaupre
Lindsay Melhuish Beaupre
GBGregory Michael Brown
Gregory Michael Brown
JKJames L. Kennedy
James L. Kennedy
Background: Sleep disturbances are a common symptom of major depressive disorder (MDD). Sleep is highly regulated by circadian rhythms, controlled by circadian genes, that act through a series of feedback loops to regulate the sleep-wake cycle. Objectives: To the best of our knowledge, a systematic review regarding the core circadian genes and their role in MDD has not been published recently. Also, a review of these genes and their role in sleep disturbances in depressed individuals appears to have never been done. We decided to integrate both concepts into one comprehensive review. Method: The review was done using the appropriate search terms in the following search engines: OVID Medline, Embase, PsycINFO and Pubmed. Results: Based on the data reviewed, none of the circadian genes appear to be associated with MDD, but some are more promising than others. These genes are: CRY1, CRY2, PER2 and NPAS2. When investigating the role of circadian genes in sleep disturbances among individuals with MDD, the most promising candidate gene is TIMELESS. Although the results in this area are limited. Conclusion: Given the promising leads from this review, future studies should investigate circadian genes in sleep disturbances among the depressed population.